- Trial phase
- Phase 3
- Time to market
- If the full upLIFT results (expected mid-December 2026) remain positive, Rezolute could file a Biologics License Application (BLA) for tumor hyperinsulinism in 2027. The congenital HI path is less clear after the sunRIZE miss, though the FDA has recommended a pre-BLA meeting. Analyst projections from 2025 suggested a potential market launch in 2027 for at least one indication.
- Why 4/10
- The next hard catalyst is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. For LGND, ersodetug is a minor royalty asset among 200+, so this catalyst has limited impact on LGND's share price. ImpactScore is 4 because there is a dated binary readout within ~1 month, but it drives only a small fraction of LGND's diversified royalty portfolio value.
The next hard catalyst for ersodetug is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. Positive results would support a BLA filing for tumor HI, while the congenital HI path remains uncertain after the sunRIZE miss. For LGND holders, this is a minor portfolio contributor; for RZLT holders, it is the primary value driver.
Price Chart
Executive Summary
Ersodetug (RZ358) is a monoclonal antibody insulin-receptor antagonist being developed by Rezolute (RZLT) for hypoglycemia caused by hyperinsulinism. The drug had a mixed clinical record: the Phase 3 sunRIZE study in congenital hyperinsulinism failed its primary endpoint in December 2025, but the Phase 3 upLIFT study in tumor hyperinsulinism met its primary endpoint with 13 of 16 responders, announced today (November 13, 2026). Through Ligand's $739M acquisition of XOMA Royalty (closed July 2026), Ligand (LGND) holds high-single to mid-teen percentage royalty rights on any future ersodetug sales. However, ersodetug is one of 200+ royalty assets in Ligand's portfolio and represents a very small fraction of its diversified revenue stream, making it a minor factor for LGND shareholders.
How It Works
Ersodetug is a lab-made antibody (a fully human monoclonal antibody) that blocks the insulin receptor. In patients with hyperinsulinism, the body produces too much insulin, causing dangerously low blood sugar. Ersodetug acts as an insulin antagonist, preventing excess insulin from signaling cells to absorb too much glucose, thereby raising and stabilizing blood sugar levels.
Trial Status
Two Phase 3 trials have been completed: sunRIZE (congenital HI) failed its primary endpoint in December 2025; upLIFT (tumor HI) met its primary endpoint with positive preliminary results announced November 13, 2026. Full topline results for upLIFT are expected by mid-December 2026. The FDA has recommended a pre-BLA meeting for the congenital HI program despite the sunRIZE miss.
The Two-Sided Case
Upcoming Catalysts
- Full topline results from Phase 3 upLIFT study in tumor HI (expected by mid-December 2026)
- Pre-BLA meeting with FDA for congenital HI program (timing TBD)
- Potential BLA submission for tumor HI if full upLIFT results remain positive
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LIGAND PHARMACEUTICALS INC 8-K LGND ·Originating report